A052260 Stock Overview
Engages in the manufacture and sale of natural materials for cosmetics, nutraceuticals, and regenerative medicines worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 1/6 |
My Notes
Capture your thoughts, links and company narrative
HYUNDAI BIOLAND Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩4,045.00 |
| 52 Week High | ₩7,900.00 |
| 52 Week Low | ₩3,865.00 |
| Beta | 0.50 |
| 1 Month Change | -7.54% |
| 3 Month Change | -30.74% |
| 1 Year Change | -18.94% |
| 3 Year Change | -52.97% |
| 5 Year Change | -63.31% |
| Change since IPO | 131.14% |
Recent News & Updates
HYUNDAI BIOLAND Co.,Ltd.'s (KOSDAQ:052260) Shareholders Might Be Looking For Exit
Dec 17
Optimistic Investors Push HYUNDAI BIOLAND Co.,Ltd. (KOSDAQ:052260) Shares Up 27% But Growth Is Lacking
Aug 11Recent updates
HYUNDAI BIOLAND Co.,Ltd.'s (KOSDAQ:052260) Shareholders Might Be Looking For Exit
Dec 17Optimistic Investors Push HYUNDAI BIOLAND Co.,Ltd. (KOSDAQ:052260) Shares Up 27% But Growth Is Lacking
Aug 11Some Investors May Be Worried About HYUNDAI BIOLANDLtd's (KOSDAQ:052260) Returns On Capital
Jul 26Is HYUNDAI BIOLANDLtd (KOSDAQ:052260) A Risky Investment?
May 25Subdued Growth No Barrier To HYUNDAI BIOLAND Co.,Ltd. (KOSDAQ:052260) With Shares Advancing 28%
May 03Impressive Earnings May Not Tell The Whole Story For HYUNDAI BIOLANDLtd (KOSDAQ:052260)
Mar 19Should You Buy HYUNDAI BIOLAND Co.,Ltd (KOSDAQ:052260) For Its Dividend?
Apr 12HYUNDAI BIOLAND Co.,Ltd's (KOSDAQ:052260) Financial Prospects Don't Look Very Positive: Could It Mean A Stock Price Drop In The Future?
Mar 08Update: HYUNDAI BIOLANDLtd (KOSDAQ:052260) Stock Gained 14% In The Last Five Years
Feb 15The Returns At HYUNDAI BIOLANDLtd (KOSDAQ:052260) Provide Us With Signs Of What's To Come
Jan 28Tread With Caution Around HYUNDAI BIOLAND Co.,Ltd's (KOSDAQ:052260) 1.5% Dividend Yield
Jan 10HYUNDAI BIOLANDLtd (KOSDAQ:052260) Takes On Some Risk With Its Use Of Debt
Dec 23Are Poor Financial Prospects Dragging Down HYUNDAI BIOLAND Co.,Ltd (KOSDAQ:052260 Stock?
Dec 05
The HYUNDAI BIOLANDLtd (KOSDAQ:052260) Share Price Is Up 55% And Shareholders Are Holding On
Nov 17Shareholder Returns
| A052260 | KR Personal Products | KR Market | |
|---|---|---|---|
| 7D | -1.3% | -1.7% | -0.04% |
| 1Y | -18.9% | -16.0% | -12.2% |
Return vs Industry: A052260 underperformed the KR Personal Products industry which returned -16% over the past year.
Return vs Market: A052260 underperformed the KR Market which returned -12.2% over the past year.
Price Volatility
| A052260 volatility | |
|---|---|
| A052260 Average Weekly Movement | 5.5% |
| Personal Products Industry Average Movement | 7.5% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.7% |
| 10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A052260 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A052260's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | n/a | Chan-Bok Jeong | www.hyundaibioland.co.kr |
HYUNDAI BIOLAND Co.,Ltd. engages in the manufacture and sale of natural materials for cosmetics, nutraceuticals, and regenerative medicines worldwide. The company’s cosmetics includes whitening, skin protection, moisturizing, anti-aging, sheet mask, and hair and body care products; and functional food ingredients comprising various nutraceuticals and general food raw ingredients.
HYUNDAI BIOLAND Co.,Ltd. Fundamentals Summary
| A052260 fundamental statistics | |
|---|---|
| Market cap | ₩121.35b |
| Earnings (TTM) | ₩7.76b |
| Revenue (TTM) | ₩121.17b |
15.6x
P/E Ratio1.0x
P/S RatioIs A052260 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A052260 income statement (TTM) | |
|---|---|
| Revenue | ₩121.17b |
| Cost of Revenue | ₩73.08b |
| Gross Profit | ₩48.09b |
| Other Expenses | ₩40.33b |
| Earnings | ₩7.76b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 258.58 |
| Gross Margin | 39.69% |
| Net Profit Margin | 6.40% |
| Debt/Equity Ratio | 22.9% |
How did A052260 perform over the long term?
See historical performance and comparisonDividends
0.9%
Current Dividend Yield19%
Payout RatioDoes A052260 pay a reliable dividends?
See A052260 dividend history and benchmarks| HYUNDAI BIOLANDLtd dividend dates | |
|---|---|
| Ex Dividend Date | Dec 27 2024 |
| Dividend Pay Date | Apr 21 2025 |
| Days until Ex dividend | 2 days |
| Days until Dividend pay date | 113 days |
Does A052260 pay a reliable dividends?
See A052260 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/28 09:09 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
HYUNDAI BIOLAND Co.,Ltd. is covered by 15 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hye Mi Kim | Cape Investment & Securities Co., Ltd. |
| Jun-Ho Byun | Eugene Investment & Securities Co Ltd. |
| Jun-Young Choi | Hanwha Investment & Securities Co., Ltd. |